What is the evidence? In horses with septic bursitis for which the organism has not yet been identified, is IV regional perfusion with amikacin or cefotaxime likely to be effective?
Fajt
Virginia R
VR
Departments of Veterinary Physiology and Pharmacology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX 77843, USA. vfajt@cvm.tamu.edu
Van House
Angela M
AM
Honnas
Clifford M
CM
D000583:Amikacin / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001170:Arthritis, Infectious / Q000175:diagnosis / Q000188:drug therapy / Q000662:veterinary*; D002062:Bursitis / Q000175:diagnosis / Q000188:drug therapy / Q000662:veterinary*; D002439:Cefotaxime / Q000008:administration & dosage / Q000627:therapeutic use; D055317:Evidence-Based Practice; D005260:Female; D006734:Horse Diseases / Q000175:diagnosis / Q000188:drug therapy*; D006736:Horses; D007794:Lameness, Animal / Q000175:diagnosis*
D000900:Anti-Bacterial Agents; D000583:Amikacin; D002439:Cefotaxime